MetaboCure is a biopharmaceutical company focused on developing novel therapies for cancer cachexia and other metabolic complications, aiming to restore patients’ strength and improve clinical outcomes.MetaboCure is developing Nuforal, an HNF4α mRNA/LNP-based drug, for the treatment of cancer cachexia.

The company has deciphered the biochemical and molecular mechanisms underlying cachexia, discovering that the transcription factor HNF4α, crucial for regulating liver metabolism, is suppressed during the disease, leading to macromolecule breakdown, which the tumor exploits to fuel its growth.

By restoring HNF4α levels in the liver of cancer mouse models, using HNF4α mRNA, the symptoms are reversed as is evident by reduced weight loss, tumor shrinkage, and improved survival rates.

Nuforal showed a very encouraging results in animal models: the weight loss and muscle wasting stopped and returned to normal, and the cancer tumor stopped growing.